Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Cipla Limited
  6. News
  7. Summary
    CIPLA   INE059A01026

CIPLA LIMITED

(CIPLA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cipla : Disclosure of related party transactions for the half year ended 30th September 2021

11/26/2021 EST

Disclosure of Related Party Transactions

for the half year ended 30th September, 2021

[pursuant to Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)]

Note: The disclosure for the half-year ended 30th September, 2021 was filed with the Stock Exchanges in XBRL

format. For the purpose of disclosure on website, an extract of the format submitted is enclosed.

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.comCorporate Identity Number L24239MH1935PLC002380

Related party transactions (1)

A. Details of related party

B. Details of related party transactions

C. Outstanding balances

Remuneration

Receivables

Payables

Sr

Name of the related party

Categories of related

Description of

CIN of related party

Purchase of

Receiving of

Equity

Dividend paid

Short term

Post

Other long‐

Termination

Share based

Others

Secured

Un

Secured

Un

parties

relationship

goods and

services

investment

employee

employment

term

benefits

payments

Secured

Secured

services

benefits

benefits

benefits

1

Dr. Y K Hamied

Promoters

Non‐executive

81.98

1.02(2)

1.00

Chairman

2

Mr. Kedar Upadhye

Key management

Global Chief Financial

0.03

1.74

0.03

0.81

0.61

personnel of entity or

Officer

parent

3

Mr. M K Hamied

Promoters

Non‐executive Vice

17.28

1.04(3)

1.00

Chairman

4

Mr. S. Radhakrishnan

Key management

Non executive Director

0.09

1.09(3)

1.00

personnel of entity or

parent

5

Mr. Umang Vohra

Key management

Managing Director and

0.16

7.40

0.12

2.56

3.22

personnel of entity or

Global Chief Executive

parent

Officer

6

Ms. Samina Hamied

Key management

Executive Vice

8.95

4.12(4)

0.11

1.82

personnel of entity or

Chairperson

parent

7

AMPSolar Power Systems Private

Associates

Associate

U74996DL2019PTC345639

7.81

0.01

1.16(5)

Limited

8

Cipla Foundation

Other related party

Entities over which the

27.69(6)

company is able to

exercise significant

influence/Control

9

GoApptiv Private Limited

Associates

Associate

U74999MH2015PTC263070

18.23(7)

6.74

10

Dr. Peter Mugyenyi

Key management

Non executive Director

0.44(3)

0.35

personnel of entity or

parent

11

Mr. Adil Zainulbhai

Key management

Non executive Director

0.36(3)

0.28

personnel of entity or

parent

12

Mr. Ashok Sinha

Key management

Non executive Director

0.38(3)

0.32

personnel of entity or

parent

13

Mr. P R Ramesh

Key management

Non executive Director

0.16(3)

0.14

personnel of entity or

parent

14

Mr. Robert Stewart

Key management

Non executive Director

0.37(3)

0.34

personnel of entity or

parent

15

Ms. Naina Lal Kidwai

Key management

Non executive Director

0.35(3)

0.28

personnel of entity or

parent

16

Ms. Punita Lal

Key management

Non executive Director

0.33(3)

0.28

personnel of entity or

parent

17

Brandmed (Pty) Limited

Associates

Associate

0.00(8)

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

Related party transactions (1)

A. Details of related party

B. Details of related party transactions

C. Outstanding balances

Remuneration

Receivables

Payables

Sr

Name of the related party

Categories of related

Description of

CIN of related party

Purchase of

Receiving of

Equity

Dividend paid

Short term

Post

Other long‐

Termination

Share based

Others

Secured

Un

Secured

Un

parties

relationship

goods and

services

investment

employee

employment

term

benefits

payments

Secured

Secured

services

benefits

benefits

benefits

18

Stempeutics Research Private

Associates

Associate

U73100KA2006PTC038256

0.20

0.39

Limited

19

Sitec Labs Private Limited

Other related party

Post Employment

1.28

Employees Group Gratuity

Benefit Trust

Scheme

20

Goldencross Pharma Private

Other related party

Post Employment

0.23

Limited Employees Group

Benefit Trust

Gratuity Fund

21

Meditab Specialities Limited

Other related party

Post Employment

0.39

Employees Comprehensive

Benefit Trust

Gratuity Scheme

22

Medispray Laboratories Private

Other related party

Post Employment

0.05

Limited Employees

Benefit Trust

Comprehensive Gratuity Scheme

23

Cipla Health Limited Employees

Other related party

Post Employment

0.10(9)

1.13

Gratuity scheme

Benefit Trust

24

Cipla Biotec Private Limited

Other related party

Post Employment

0.01

Employees Gratuity Fund

Benefit Trust

25

Cipla Limited Employees Gratuity

Other related party

Post Employment

12.5(9)

1.45

Fund

Benefit Trust

26

Cipla Limited Employees

Other related party

Post Employment

19.34(9)

10.69

Provident fund

Benefit Trust

Notes

  1. Columns where there were nil transactions and form part of the XBRL format submitted to Stock Exchanges have not been disclosed. These include ‐ Sale of goods, Purchase of fixed assets, Sale of fixed assets, Rendering of services, Leases, Loans and advances given, Loans and advances taken, Loans and advances given that are repaid, Loans and advances taken that are repaid, Deposits placed, Deposits taken, Transfer of research and development, Transfer under lease agreement, Impairment in equity investment, Expense for bad or doubtful debts, Guarantees or collateral given, Guarantees or collateral taken, Interest income, Interest paid, Dividend income, Management contracts including deputation of employees, Settlement of liabilities by entity on behalf of related party, Receivables secured and unsecured, Loans and advances taken secured and unsecured, Loans and advances given secured and unsecured, Deposits placed secured and unsecured, Deposits taken secured and unsecured, Guarantees and collateral given secured and unsecured, Guarantees and collateral taken secured and unsecured, Investment in equity secured and unsecured, Provision for doubtful debt secured and unsecured.
  2. Includes director's commission, sitting fees and rent received
  3. Includes director's commission and sitting fees
  4. Short‐term employee benefits includes commission amount of ₹ 1.75 cr
  5. Includes investment in Compulsorily Convertible Debentures
  6. Includes contribution towards CSR activities
  7. Rendering of services includes service charges and reimbursement paid
  8. Purchase of goods ‐ ₹ 14,702
  9. Includes contribution during the year

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

Disclaimer

Cipla Ltd. published this content on 26 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 December 2021 14:20:04 UTC.


ę Publicnow 2021
All news about CIPLA LIMITED
07:41aCIPLA : Earnings Call Transcript Q3FY22
PU
01/28Nomura Adjusts Cipla's Price Target to 1,195 Indian Rupees From 1,051 Indian Rupes, Kee..
MT
01/26Cipla Limited Announces Resignation of Naina Lal Kidwai as Independent Director, Effect..
CI
01/26Cipla Books Slightly Lower Consolidated Profit in Fiscal Q3; EPS Beats Estimates
MT
01/25Cipla to Transfer India-Based US Undertaking and Consumer Business to Subsidiaries
MT
01/25CIPLA : Q3 FY22 Press release
PU
01/25CIPLA : Q3 FY22 Investor presentation
PU
01/25CIPLA : Extract of Unaudited Consolidated Financial Results – 31st December 2021
PU
01/25CIPLA : Unaudited financial results (standalone and consolidated) for the quarter and nine..
PU
01/25Cipla Limited Reports Earnings Results for the Third Quarter and Nine Months Ended Dece..
CI
More news
Analyst Recommendations on CIPLA LIMITED
More recommendations
Financials
Sales 2022 216 B 2 881 M 2 881 M
Net income 2022 28 197 M 376 M 376 M
Net cash 2022 21 855 M 291 M 291 M
P/E ratio 2022 26,7x
Yield 2022 0,54%
Capitalization 752 B 10 028 M 10 024 M
EV / Sales 2022 3,38x
EV / Sales 2023 3,01x
Nbr of Employees 25 672
Free-Float 61,9%
Chart CIPLA LIMITED
Duration : Period :
Cipla Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CIPLA LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 35
Last Close Price 932,25 INR
Average target price 1 069,83 INR
Spread / Average Target 14,8%
EPS Revisions
Managers and Directors
Umang Vohra Global Chief Executive Officer, MD & Director
Raju Mistry President & Global Chief People Officer
Kedar Upadhye Global Chief Financial Officer
Yusuf Khwaja Hamied Non-Executive Chairman
Jaideep A. Gogtay Global Chief Medical Officer
Sector and Competitors